Joint Formulary & PAD

Pitolisant hydrochloride - Narcolepsy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Tablets
Associated Icons :
BNF SPC
CD
ICB
NICE
Restrictions / Comments :
Important
QVH = local sleep specialist centre

PAD Profile

ChemicalSubstance :
Pitolisant hydrochloride
Indication :
Narcolepsy
Group Name :
Keywords :
fatigue, sleepiness, cataplexy
Brand Names Include :
Wakix
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Pitolisant hydrochloride is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Narcolepsy.

Committee Recommendations (1)

The Surrey and North West Sussex Area Prescribing Committee recommends pitolisant (Wakix®) monotherapy for the management of narcolepsy with or without cataplexy.

The APC recommend a RED traffic light status for the use of pitolisant monotherapy for this indication.

Combination treatment will not be routinely funded and if combination treatment is considered clinically appropriate, an individual funding request (IFR) will need to be completed by the specialist for consideration of commissioner funding.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.